Clinical validation of full genotyping CLART® HPV4S assay on SurePath and ThinPrep collected screening samples according to the international guidelines for human papillomavirus test requirements for cervical screening | BMC Cancer | Full Text

Clinical validation of full genotyping CLART® HPV4S assay on SurePath and ThinPrep collected screening samples according to the international guidelines for human papillomavirus test requirements for cervical screening | BMC Cancer | Full Text

Clinical validation of full genotyping CLART® HPV4S assay on SurePath and ThinPrep collected screening samples according to the international guidelines for human papillomavirus test requirements for cervical screening

To ensure the highest quality of human papillomavirus (HPV) testing in primary cervical cancer screening, novel HPV assays must be evaluated in accordance with the international guidelines. Furthermore, HPV as...

Authors:Ditte Møller Ejegod, Camilla Lagheden, Ramya Bhatia, Helle Pedersen, Elia Alcañiz Boada, Karin Sundström, Javier Cortés, F. Xavier Bosch Josë, Kate Cuschieri, Joakim Dillner and Jesper Bonde

Citation:BMC Cancer 2020 20:396

Content type:Research article

Published on: 6 May 2020

• ViewFull Text
 
• ViewPDF